Nicox partner Kowa files NDA for NCX 470 glaucoma eye drop
Nicox SA has announced that its exclusive US licensee, Kowa Company, has submitted a New Drug Application to the FDA for NCX 470, a novel nitric oxide-donating bimatoprost eye drop indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The filing triggers a €3 million milestone payment to the French ophthalmology company, with a further payment due upon approval.
NCX 470, also known as K-911 and generically designated bimatoprost grenod, combines bimatoprost, a prostaglandin analogue already established in glaucoma therapy, with a nitric oxide-donating moiety intended to provide an additional pressure-lowering mechanism via the trabecular meshwork pathway. The NDA is supported by two Phase 3 trials, Mont Blanc and Denali, which the company says demonstrated clinically meaningful IOP reductions with a favourable safety profile, though specific magnitude-of-effect data and comparator details were not disclosed in the release.
The FDA is expected to conduct a standard 12-month review, placing a potential approval decision in mid-2027. Kowa has indicated it is targeting a US commercial launch before the end of 2027.
Regulatory and commercial path
Doug Hubatsch, chief scientific officer of Nicox, said the Phase 3 data formed a strong basis for the submission and that the company looked forward to working with Kowa and the FDA through the review process. Junichi Kawagoe, director and senior managing executive officer of Kowa, said NCX 470's US launch was planned "shortly after approval of the NDA in mid-2027."
Beyond the US, Kowa holds rights in Japan, where it has an established glaucoma commercial infrastructure, and Phase 3 trials were initiated there in the summer of 2025. Ocumension Therapeutics holds rights for China, South Korea and Southeast Asia, with regulatory submissions expected to follow the US filing in short order. Under the partnership structure, Kowa and Ocumension bear all regulatory and commercialisation costs, while Nicox retains eligibility for milestone payments and royalties on global sales.
Market context
Open-angle glaucoma is the leading cause of irreversible blindness worldwide and represents a substantial addressable market for ocular hypotensive agents. The prostaglandin analogue class, which includes latanoprost, travoprost and the original bimatoprost formulation (marketed as Lumigan and generically available), dominates first-line prescribing in many markets. Competition is intensifying, however, as fixed-dose combinations and next-generation agents seek to differentiate on tolerability, dosing convenience and adherence.
Nicox's existing product VYZULTA, also a nitric oxide-donating compound licensed exclusively to Bausch + Lomb, is already marketed in the US and more than 15 territories, providing a partial proof of concept for the nitric oxide-donating approach in glaucoma. NCX 470's differentiation case will likely rest on head-to-head efficacy data from the Mont Blanc and Denali trials, and investors will be watching for those full datasets, including comparator arm performance, ahead of any FDA advisory committee meetings or labelling negotiations.
For Nicox, approval and launch would convert what has been a milestone-and-royalty model into a more visible recurring revenue stream, as Kawagoe's comments about a "sustainable and recurrent revenue stream" indicate. At its current Euronext Growth Paris listing, the company's equity story depends heavily on this regulatory inflection point, making the mid-2027 PDUFA window a critical catalyst.